These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 8585282

  • 1. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides.
    Fattom A, Li X, Cho YH, Burns A, Hawwari A, Shepherd SE, Coughlin R, Winston S, Naso R.
    Vaccine; 1995 Oct; 13(14):1288-93. PubMed ID: 8585282
    [Abstract] [Full Text] [Related]

  • 2. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate.
    Fattom A, Shiloach J, Bryla D, Fitzgerald D, Pastan I, Karakawa WW, Robbins JB, Schneerson R.
    Infect Immun; 1992 Feb; 60(2):584-9. PubMed ID: 1730492
    [Abstract] [Full Text] [Related]

  • 3. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.
    Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB.
    Infect Immun; 1993 Mar; 61(3):1023-32. PubMed ID: 8432585
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.
    Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, Karakawa WW, Robbins JB.
    Infect Immun; 1990 Jul; 58(7):2367-74. PubMed ID: 2114365
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
    Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC.
    Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL.
    Schneerson R, Fattom A, Szu SC, Bryla D, Ulrich JT, Rudbach JA, Schiffman G, Robbins JB.
    J Immunol; 1991 Oct 01; 147(7):2136-40. PubMed ID: 1918948
    [Abstract] [Full Text] [Related]

  • 7. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine.
    Ho MM, Bolgiano B, Martino A, Kairo SK, Corbel MJ.
    Hum Vaccin; 2006 Oct 01; 2(3):89-98. PubMed ID: 17012902
    [Abstract] [Full Text] [Related]

  • 8. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J.
    Infect Immun; 2001 Jan 01; 69(1):297-306. PubMed ID: 11119518
    [Abstract] [Full Text] [Related]

  • 9. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M, St Michael F, Ali A, Jabbar A, Cairns C, Hayes AC, Rahman M, Iqbal M, Haque A, Cox AD.
    J Immunol Methods; 2017 Nov 01; 450():27-33. PubMed ID: 28735760
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.
    Welch PG, Fattom A, Moore J, Schneerson R, Shiloach J, Bryla DA, Li X, Robbins JB.
    J Am Soc Nephrol; 1996 Feb 01; 7(2):247-53. PubMed ID: 8785394
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines.
    Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC.
    Infect Immun; 1994 Nov 01; 62(11):5048-54. PubMed ID: 7927787
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.
    Fattom AI, Sarwar J, Ortiz A, Naso R.
    Infect Immun; 1996 May 01; 64(5):1659-65. PubMed ID: 8613375
    [Abstract] [Full Text] [Related]

  • 19. Preparation and characterization of a Staphylococcus aureus capsular polysaccharide-protein conjugate prepared by a low cost technique: a proof-of-concept study.
    Pujato N, Díaz G, Barbagelata MS, Vicco MH, Calvinho LF, Marcipar IS.
    Appl Biochem Biotechnol; 2015 Jan 01; 175(1):141-54. PubMed ID: 25245681
    [Abstract] [Full Text] [Related]

  • 20. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
    Cui C, Carbis R, An SJ, Jang H, Czerkinsky C, Szu SC, Clemens JD.
    Clin Vaccine Immunol; 2010 Jan 01; 17(1):73-9. PubMed ID: 19889941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.